Advertisement

Injection of gadoversetamide, a new gadolinium chelate: ultra-high dose usage for MRI of the central nervous system

  • M. Kuhn
  • H. Youssef
  • R. Grossman
  • K. Maravilla
  • G. Hammer
  • L. Meis
  • J. Underwood
Conference paper

Abstract

The objective of this phase II study was to evaluate the safety and effectiveness and the optimal dosage of gadoversetamide. Eighty-one patients underwent two complete MRI examinations of the head or spine between 1 and 5 days apart. Each received two different randomized intravenous doses of gadoversetamide, either 0.1,0.3 or 0.5 mmol/kg. Identical imaging parameters and injection rates were maintained. Baseline and follow-up hematologic and blood and urine chemistry tests were obtained. Vital signs were obtained at predetermined intervals. Seventy-three patients completed the study, for a total of 146 injections. No clincally significant or life-threatening adverse effects were noted, nor were clinically significant changes in vital signs or laboratory values attributable to the contrast agent observed. Gadoversetamide is a new non-ionic gadolinium chelate which, based on these preliminary studies, appears to be safe and effective over a wide range of doses for MRI of the head and spine

key words

Gadoversetamide Magnetic resonance imaging Brain Spine 

References

  1. 1.
    Vogl TJ, Mack MG, Juergens M, et al (1994) MR diagnosis of head and neck tumors: Comparison of contrast enhancement with triple-dose gadodiamide and standard-dose gadopentetate dimeglumine in the same patients. AJR 163:425–432.PubMedCrossRefGoogle Scholar
  2. 2.
    Sze G, Brant-Zawadski M, Haughton VM, et al (1991) Multicenter study of gadodiamide injection as a contrast agent in MR imaging of the brain and spine. Radiology 181:693–699.PubMedGoogle Scholar
  3. 3.
    Wagoner MV, O’Toole M, Quay SC (1990) Nonionic magnetic resonance imaging contrast agents. Clinical trial experience of safety, tolerance, and efficacy of gadodiamide injection. Invest Radiol 25:S39–S41.PubMedCrossRefGoogle Scholar
  4. 4.
    Greco A, McNamara MT, Lanthiez P, Quay SC, Michelozzi G (1990) Gadodiamide injection: nonionic gadolinium chelate for MR imaging of the brain and spine — phase II–III clinical trial. Radiology 176:451–456.PubMedGoogle Scholar
  5. 5.
    Yuh TC, Engelken JD, Muhonen MG, Mayr NA, Fisher DJ, Ehrhardt JC (1992) Experience with high-dose gadolinium MR imaging on the evaluation of brain metastases. AJNR 13:335–345.PubMedGoogle Scholar
  6. 6.
    Yuh TC, Fisher DJ, Engelken JD, et al (1991) MR evaluation of CNS tumors: dose comparison study with gadopentetate dimeglumine and gadoteridol. Radiology 180:485–491.PubMedGoogle Scholar
  7. 7.
    Runge VM, Kirsch JE, Thomas GS (1991) High dose applications of gadolinium chelates in magnetic resonance imaging. Magn Reson Med 22:358–363.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1995

Authors and Affiliations

  • M. Kuhn
    • 1
  • H. Youssef
    • 1
  • R. Grossman
    • 2
  • K. Maravilla
    • 3
  • G. Hammer
    • 1
  • L. Meis
    • 1
  • J. Underwood
    • 1
  1. 1.Division of NeuroradiologySouthern Illinois University School of MedicineSpringfieldUSA
  2. 2.Department of RadiologyUniversity of PennsylvaniaPhiladelphiaUSA
  3. 3.Department of RadiologyUniversity of WashingtonSeattleUSA

Personalised recommendations